Schiff Nutrition International, Inc., (NYSE:WNI), formed a
Scientific Advisory Board and named Dr. Richard H. Carmona, 17th
Surgeon General of the United States, as chairman.
Dr. Carmona stated: “Throughout my career, I have been deeply
committed to public health. Schiff Nutrition is focused on using
sound science in developing products to meet consumer needs, and I
look forward to working with the team.”
“Schiff Nutrition welcomes Dr. Carmona,” stated Tarang Amin,
president and chief executive officer. “We are forming the
Scientific Advisory Board to provide guidance and to facilitate
connections for new product ideas and technology platforms. As one
of the world’s leading experts in public health, Dr. Carmona
believes in the importance of strong nutrition. We are honored he
will chair our advisory board as we strive to lead product
innovation.”
Richard H. Carmona, M.D., M.P.H., FACS
- 17th Surgeon General of the United
States (2002-2006)
- President, Canyon Ranch Institute
- Vice Chairman, Canyon Ranch
- Distinguished Professor, Mel and Enid
Zuckerman College of Public Health, University of AZ
In 2002, Dr. Carmona, 61, was nominated by the President of the
United States and unanimously confirmed by the United States Senate
to become the 17th Surgeon General. Dr. Carmona was selected
because of his extensive experience in public health, clinical
sciences, health care management, preparedness, and his commitment
to prevention as an effective means to improve public health and
reduce health care costs while improving the quality and quantity
of life. As Surgeon General, Dr. Carmona focused on prevention,
preparedness, health disparities, health literacy, and global
health to include health diplomacy. He also issued many landmark
Surgeon General communications during his tenure, including the
definitive Surgeon General's Report about the dangers of
second-hand smoke and the first-ever Surgeon General’s Report on
bone health and osteoporosis, which provided much needed
information on bone health, an often overlooked aspect of physical
health, and which identified the relevant scientific data,
rigorously evaluated and summarized the evidence, and determined
conclusions.
In 2006, Dr. Carmona was named president of Canyon Ranch
Institute, a 501(c)3 non-profit organization. Canyon Ranch
Institute catalyzes the possibility of optimal health for all
people by translating the best practices of Canyon Ranch and its
partners to help educate, inspire, and empower every person to
prevent disease and choose a life of wellness.
Trained in general and vascular surgery, Dr. Carmona also
completed a National Institutes of Health-sponsored fellowship in
trauma, burns, and critical care. Dr. Carmona was then recruited
jointly by the Tucson (Arizona) Medical Center and the University
of Arizona to start and direct Arizona's first regional trauma care
system. He went on to become the chairman of the State of Arizona
Southern Regional Emergency Medical System, a professor of surgery,
public health and family and community medicine at the University
of Arizona, and the Pima County Sheriff's Department surgeon and
deputy sheriff. He is also a Fellow of the American College of
Surgeons.
Dr. Carmona has published extensively and received numerous
awards, decorations, and local and national recognitions for his
achievements. A strong supporter of community service, he has
served on community and national boards and provided leadership to
many diverse organizations. Dr. Carmona serves as chairperson of
the Partnership to Fight Chronic Disease, as health and wellness
chairperson of the Strategies to Overcome and Prevent (STOP)
Obesity Alliance, and as chair of the Time to Talk CARDIO advisory
board.
Dr. Carmona is also vice chairman of Canyon Ranch, a leading
health and wellness company. In this role, he oversees health
strategy and policy for all Canyon Ranch businesses. In addition,
he is the first Distinguished Professor of Public Health at the Mel
and Enid Zuckerman College of Public Health at the University of
Arizona. He earned an associate of arts degree from Bronx Community
College of the City University of New York, a Bachelor of Science
degree from the University of California, San Francisco, and
medical degree from the University of California Medical School,
where he was awarded the prestigious gold-headed cane as the top
graduate. While serving in the U.S. Army, he became a
combat-decorated Special Forces Vietnam veteran.
About Schiff Nutrition
Schiff Nutrition International, Inc. develops, manufactures,
markets and distributes branded and private label vitamins,
nutritional supplements and nutrition bars in the United States and
throughout the world. Schiff’s portfolio of well-known brands
includes Schiff Move Free®, Schiff® Vitamins, Schiff MegaRed®,
Schiff Mega-D3™, Schiff Tiger's Milk®, Schiff Sustenex, and Schiff
Digestive Advantage. To learn more about Schiff, please visit the
web site www.schiffnutrition.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that are based
on management’s beliefs and assumptions, current expectations,
estimates, and projections. These statements are subject to known
and unknown risks and uncertainties, certain of which are beyond
the company’s ability to control or predict, and therefore, actual
results may differ materially. Any forward-looking statements are
made pursuant to the Private Securities Litigation Reform Act of
1995 and, as such, speak only as of the date hereof. Schiff
Nutrition disclaims any obligation to update any forward-looking
statements whether as a result of new information, future events or
otherwise. You are cautioned not to place undue reliance on these
forward-looking statements.
Important factors that may cause actual results of Schiff
Nutrition to differ materially from those expressed or implied by
such forward-looking statements include, but are not limited
to: members of our Scientific Advisory Board may not continue
service, dependence on sales of Schiff Move Free product and the
joint care category, dependence on sales of Schiff MegaRed product,
dependence on individual customers, adverse publicity or consumer
perception regarding our nutritional supplements and/or their
ingredients, similar products distributed by other companies or the
nutritional supplement industry generally, the impact of
competitive products and pricing pressure (including expansion of
private label products), the inability to successfully bid on new
and existing private label business, the impact of raw material
pricing, availability and quality (particularly relating to joint
care products and ingredients from third-party suppliers outside
the United States, including China), claims that our products
infringe the intellectual property rights of others, the inability
to enforce or protect our intellectual property rights and
proprietary techniques against infringement, the inability to
successfully launch and maintain sales (especially in the joint
care and omega-3 categories) outside of the United States while
maintaining the integrity of the products sold and complying with
local regulations, the inability to appropriately respond to
changing consumer preferences and demand for new products, the
inability to gain or maintain market distribution for new products
or product enhancements, including products in the probiotic space,
litigation and government or administrative regulatory action in
the United States and internationally, including FDA enforcement
and product liability claims, the inability or increased cost to
obtain sufficient levels of product liability and general
insurance, the inability to comply with existing or new
regulations, both in the United States and abroad, and adverse
actions regarding product formulation, claims or advertising,
product recalls or a significant amount of product returns,
dependence on a single manufacturing facility and potential
disruptions of our manufacturing operations, the inability to find
strategic transaction opportunities or the inability to
successfully consummate or integrate a strategic transaction
(including the inability to successfully integrate the assets
recently acquired from Ganeden), the inability to maintain or
attract key personnel, interruptions to our information technology
systems, control by our principal stockholders, and other factors
indicated from time to time in the company’s SEC reports, copies of
which are available upon request from the company’s investor
relations department or may be obtained at the SEC's web site
(www.sec.gov). These risks and
uncertainties should be carefully considered before making an
investment decision with respect to shares of our common stock.
Schiff Nutrit (NYSE:WNI)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Schiff Nutrit (NYSE:WNI)
Gráfica de Acción Histórica
De May 2023 a May 2024
